实用药物与临床
實用藥物與臨床
실용약물여림상
Practical Pharmacy and Clinical Remedies
2015年
9期
1119-1122
,共4页
蒋辉华%林琳%洪卫军%郑海滨
蔣輝華%林琳%洪衛軍%鄭海濱
장휘화%림림%홍위군%정해빈
阿托伐他汀%丁苯酞%急性脑梗死
阿託伐他汀%丁苯酞%急性腦梗死
아탁벌타정%정분태%급성뇌경사
Atorvastatin%Butylphthalide%Acute cerebral infarction
目的 比较常规剂量和高剂量阿托伐他汀与丁苯酞联用治疗急性脑梗死的临床疗效. 方法选取我院神经内科2013年5月至2014年5 月收治的急性脑梗死患者110 例,采用随机数字表法分为A组( 55例)和B组(55例). A组患者采用常规剂量阿托伐他汀与丁苯酞联用治疗,B组患者则采用高剂量阿托伐他汀与丁苯酞联用治疗;比较两组患者的临床疗效,治疗前后比较美国国立卫生院卒中量表评分( NIHSS)、总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、超敏 C 反应蛋白(hs-CRP)和基质金属蛋白酶-9(MMP-9)水平、颈动脉内膜中层厚度(IMT)及粥样硬化斑块面积等. 结果 治疗后, B组患者临床治疗总有效率高于 A 组( 90.91% vs. 60.00%, P <0.05 );NIHSS 评分低于 A 组( 3. 19 ± 0.67 vs. 5. 71 ±1. 04,P<0.05);TC、TG、HDL-C、LDL-C、hs-CRP、MMP-9 水平均优于 A组(P<0.05);IMT和粥样硬化斑块面积水平均优于A组(P<0.05). 结论 高剂量阿托伐他汀与丁苯酞联用治疗急性脑梗死,可有效促进神经功能恢复,抑制动脉粥样斑块形成,并有助于改善血脂指标及炎症反应水平,疗效优于低剂量阿托伐他汀.
目的 比較常規劑量和高劑量阿託伐他汀與丁苯酞聯用治療急性腦梗死的臨床療效. 方法選取我院神經內科2013年5月至2014年5 月收治的急性腦梗死患者110 例,採用隨機數字錶法分為A組( 55例)和B組(55例). A組患者採用常規劑量阿託伐他汀與丁苯酞聯用治療,B組患者則採用高劑量阿託伐他汀與丁苯酞聯用治療;比較兩組患者的臨床療效,治療前後比較美國國立衛生院卒中量錶評分( NIHSS)、總膽固醇(TC)、三酰甘油(TG)、高密度脂蛋白膽固醇(HDL-C)、低密度脂蛋白膽固醇(LDL-C)、超敏 C 反應蛋白(hs-CRP)和基質金屬蛋白酶-9(MMP-9)水平、頸動脈內膜中層厚度(IMT)及粥樣硬化斑塊麵積等. 結果 治療後, B組患者臨床治療總有效率高于 A 組( 90.91% vs. 60.00%, P <0.05 );NIHSS 評分低于 A 組( 3. 19 ± 0.67 vs. 5. 71 ±1. 04,P<0.05);TC、TG、HDL-C、LDL-C、hs-CRP、MMP-9 水平均優于 A組(P<0.05);IMT和粥樣硬化斑塊麵積水平均優于A組(P<0.05). 結論 高劑量阿託伐他汀與丁苯酞聯用治療急性腦梗死,可有效促進神經功能恢複,抑製動脈粥樣斑塊形成,併有助于改善血脂指標及炎癥反應水平,療效優于低劑量阿託伐他汀.
목적 비교상규제량화고제량아탁벌타정여정분태련용치료급성뇌경사적림상료효. 방법선취아원신경내과2013년5월지2014년5 월수치적급성뇌경사환자110 례,채용수궤수자표법분위A조( 55례)화B조(55례). A조환자채용상규제량아탁벌타정여정분태련용치료,B조환자칙채용고제량아탁벌타정여정분태련용치료;비교량조환자적림상료효,치료전후비교미국국립위생원졸중량표평분( NIHSS)、총담고순(TC)、삼선감유(TG)、고밀도지단백담고순(HDL-C)、저밀도지단백담고순(LDL-C)、초민 C 반응단백(hs-CRP)화기질금속단백매-9(MMP-9)수평、경동맥내막중층후도(IMT)급죽양경화반괴면적등. 결과 치료후, B조환자림상치료총유효솔고우 A 조( 90.91% vs. 60.00%, P <0.05 );NIHSS 평분저우 A 조( 3. 19 ± 0.67 vs. 5. 71 ±1. 04,P<0.05);TC、TG、HDL-C、LDL-C、hs-CRP、MMP-9 수평균우우 A조(P<0.05);IMT화죽양경화반괴면적수평균우우A조(P<0.05). 결론 고제량아탁벌타정여정분태련용치료급성뇌경사,가유효촉진신경공능회복,억제동맥죽양반괴형성,병유조우개선혈지지표급염증반응수평,료효우우저제량아탁벌타정.
Objective To compare the clinical effects of two doses of atorvastatin combined with bu-tylphthalide on acute cerebral infarction. Methods 110 patients with acute cerebral infarction in Neurology Department in our hospital were chosen from May 2013 to May 2014 and randomly divided into 2 groups. Patients in group A ( n=55) were given conventional dose of atorvastatin combined with butylphthalide,patients in treatment group (n=55) were given high dose atorvastatin combined with butylphthalide treatment. The clinical efficacy,National Institutes of Health Stroke Scale ( NIHSS) ,total cholesterol ( TC) ,three glycerol ( TG) ,high density lipoprotein cholesterol ( HDL-C),low density lipoprotein cholesterol (LDL-C),high sensitive C reactive protein (hs-CRP) and matrix metalloprotei-nase-9 (MMP-9) level and carotid intimal medial thickness (IMT) and atherosclerotic plaque area before and after treatment were observed. Results The total effective rate of group B was higher than that of group A ( 90.91%vs. 60.00%,P<0.05). The NIHSS score of group B was lower than that of group A (3. 19 ± 0.67 vs. 5. 71 ± 1. 04, P<0.05). The levels of TC,TG,HDL-C,LDL-C,hs-CRP,MMP-9,IMT and atherosclerotic plaque area of group B were better than those of group A (P<0.05). Conclusion Comapred with conventional dose of atorvastatin,high do-ses atorvastatin combined with butylphthalide on acute cerebral infarction can efficiently promote the recovery process of neurological function,inhibit the formation of atherosclerosis plaque,and it is helpful to improve the level of blood lipid and inflammatory reaction index.
